V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Sch?nek?s, A. Rost, H. Neuhaus, C. Haag, M. Clemens, B. Heinrich, U. Vehling-Kaiser, M. Fuchs, D. Fleckenstein, W. Gesierich, D. Uthgenannt, H. Einsele, A. Holstege, A. Hinke, A. Schalhorn and R. Wilkowski, “Randomized Phase III Trial of Gemcitabine plus Cisplatin Compared with Gemcitabine Alone in Advanced Pancreatic Cancer,” Journal of Clinical Oncology, Vol. 24, No. 24, 2006, pp. 3946-3952. doi:10.1200/JCO.2005.05.1490

has been cited by the following article:

• TITLE: Management of the Case of a Young Female Patient with Multiple Malignancies and Germline R24P CDKN2A Gene Mutation

  AUTHORS: Gabriella Uhercsák, Ágnes Dobi, Roland Gyulai, Judit Oláh, László Kaizer, Katalin Ormándi, Adrienne Cserháti, György Lázár, Gyula Farkas, Zsuzsanna Kahán

  KEYWORDS: Breast Cancer; Melanoma; Pancreatic Cancer; R24P CDKN2A Gene Mutation

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.7A, July 17, 2013

  ABSTRACT: The case of a young female patient with metachronous primary melanomas, advanced breast and pancreatic cancers is reported. The 5 different tumors diagnosed within six years, were managed with curative intent. Genetic analysis revealed the mutation of the R24P CDKN2A gene in a heterozygote form in both the patient and her father. Careful tertiary prevention during the follow-up of the patient is needed.